603707.SS
603707.SS
CNE100002WP3
NANJING KING-FRIEND BIOCHEMICAL
Loading chart...

Company Profile

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.

Related stocks

300363.SZ
300363.SZ • China
PORTON
23.68 CNY
1.93B USD 1Y -9.3%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%
000766.SZ
000766.SZ • China
TONGHUA GOLDEN HORSE
14.97 CNY
2.16B USD 1Y -40.1%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
600267.SS
600267.SS • China
ZHEJIANG HISUN PHARMACEUTICAL C
11.94 CNY
2.11B USD 1Y +13.5%
002399.SZ
002399.SZ • China
HEPALINK
9.89 CNY
2.17B USD 1Y -16.7%
300725.SZ
300725.SZ • China
PHARMABLOCK
51.01 CNY
1.78B USD 1Y +22.3%
300601.SZ
300601.SZ • China
KANGTAI BIOLOGICAL
13.44 CNY
2.25B USD 1Y -20.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
34.5% p.a.
Max Drawdown (5Y)
-80.0%
Sharpe Ratio (5Y)
-0.69
Beta Factor
0.44
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (34.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -80.0% in the extended horizon.
ende